Goldman Sachs Group Inc Regenxbio Inc. Transaction History
Goldman Sachs Group Inc
- $596 Billion
- Q1 2025
A detailed history of Goldman Sachs Group Inc transactions in Regenxbio Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 752,727 shares of RGNX stock, worth $6.29 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
752,727
Previous 752,727
-0.0%
Holding current value
$6.29 Million
Previous $5.38 Million
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding RGNX
# of Institutions
182Shares Held
45.4MCall Options Held
64.9KPut Options Held
103K-
Black Rock Inc. New York, NY8.61MShares$72 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.79MShares$40.1 Million3.6% of portfolio
-
Jpmorgan Chase & CO New York, NY4.36MShares$36.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$29 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.07MShares$17.3 Million0.0% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $361M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...